The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 25, 2025
Filed:
Nov. 12, 2020
Applicants:
Seattle Children's Hospital, Seattle, WA (US);
University of Washington, Seattle, WA (US);
Inventors:
Michael C. Jensen, Bainbridge Island, WA (US);
Suzie Pun, Seattle, WA (US);
Nataly Kacherovsky, Seattle, WA (US);
Assignees:
Seattle Children's Hospital, Seattle, WA (US);
University of Washington, Seattle, WA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); C12N 9/12 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 35/28 (2013.01); A61K 38/1774 (2013.01); A61K 38/179 (2013.01); A61K 38/1793 (2013.01); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/71 (2013.01); C07K 14/7151 (2013.01); C07K 16/2818 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/12 (2013.01); C12N 15/85 (2013.01); C12Y 207/10001 (2013.01); A61K 2035/124 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/14 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2800/90 (2013.01);
Abstract
Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human T-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered T cells are isolated utilizing a two-stage MTX selection that employs increasing concentrations of MTX.